Lessons from a BACE1 inhibitor trial: Off‐site but not off base
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by formation of neuritic plaque primarily composed of a small filamentous protein called amyloid‐β peptide (Aβ). The rate‐limiting step in the production of Aβ is the processing of Aβ precursor protein (APP) by β‐site APP‐cleaving enzyme (BACE1). Hence, BACE1 activity plausibly plays a rate‐limiting role in the generation of potentially toxic Aβ within brain and the development of AD, thereby making it an interesting drug target. A phase II trial of the promising LY2886721 inhibitor of BACE1 was suspended in June 2013 by Eli Lilly and Co., due to possible liver toxicity. This outcome was apparently a surprise to the study's team, particularly since BACE1 knockout mice and mice treated with the drug did not show such liver toxicity. Lilly proposed that the problem was not due to LY2886721 anti‐BACE1 activity. We offer an alternative hypothesis, whereby anti‐BACE1 activity may induce apparent hepatotoxicity through inhibiting BACE1's processing of β‐galactoside α‐2,6‐sialyltransferase I (STGal6 I). In knockout mice, paralogues, such as BACE2 or cathepsin D, could partially compensate. Furthermore, the short duration of animal studies and short lifespan of study animals could mask effects that would require several decades to accumulate in humans. Inhibition of hepatic BACE1 activity in middle‐aged humans would produce effects not detectable in mice. We present a testable model to explain the off‐target effects of LY2886721 and highlight more broadly that so‐called off‐target drug effects might actually represent off‐site effects that are not necessarily off‐target. Consideration of this concept in forthcoming drug design, screening, and testing programs may prevent such failures in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“Hence, the b-site APP-cleaving enzyme 1 (BACE1), the rate-limiting enzyme in the pathway that produces Ab peptide from the Ab precursor protein (APP) [11], is considered a promising target for prevention or modification of AD [12].”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Role of Quinones in Toxicology
Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., & Monks, T. J. (2000) · Chemical Research in Toxicology · doi:10.1021/tx9902082 · Cited by 1,703
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“For example, peripheral nerves in newborn BACE1 knockout mice are thinly myelinated [23,24].”
Bace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · cited 1×
“For example, peripheral nerves in newborn BACE1 knockout mice are thinly myelinated [23,24].”
Liu, R.-Y., Zhou, J.-N., van Heerikhuize, J., Hofman, M. A., & Swaab, D. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5394 · Cited by 304
Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198 · cited 1×
“Specific miRNAs, such as miR-101 and miR-153, regulate APP expression and are dysfunctional in AD brain [57,58].”
Long, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187
Self-citation
Cited by
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Self-citationLong, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187
Self-citationAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
Metadata
- Authors
- Lahiri, D. K., Maloney, B., Long, J. M., & Greig, N. H.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-02-14
- Volume
- 10
- Issue
- 5S
- Pages
- S411-9
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2120642977
- Cited by
- 82
- References
- 11
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lessons from a BACE1 inhibitor trial: Off‐site but not off base. https://app.cochat.ai/papers/10.1016/j.jalz.2013.11.004
- The paper
- Lahiri, D. K., Maloney, B., Long, J. M., & Greig, N. H. (2014). Lessons from a BACE1 inhibitor trial: Off‐site but not off base. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.11.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.